MedTrace Logo

Real-Time Continuous Glucose Monitoring (RT-CGM) in Patients With Type 1 Diabetes at High Risk for Low Glucose Values Using Multiple Daily Injections (MDI) in Germany (HYPODE-STUDY)

NCT02671968 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 141

Last updated 2018-03-12

No results posted yet for this study

Summary

Demonstrate that usage of RT-CGM (Real time continuous glucose monitoring) reduces the frequency of low CGM-recorded glucose events in patients using MDI (Multiple daily injections) that are at risk for hypoglycemic events.

Conditions

Interventions

DEVICE

Continuous Glucose Monitoring System

Sponsors & Collaborators

  • DexCom, Inc. a Delaware corporation, USA

    collaborator UNKNOWN

  • Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Germany

    collaborator UNKNOWN

  • Science Consulting in Diabetes

    lead INDUSTRY

Principal Investigators

  • Norbert Hermanns, Prof. · Forschungsinstitut Diabetes-Akademie Bad Mergentheim (FIDAM)

Study Design

Allocation
RANDOMIZED
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2017-07-14
Completion
2017-10-24

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02671968 on ClinicalTrials.gov